Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease stage4
  3. NCT05042206

Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease

Chronic Kidney Disease stage4 Clinical Trial

Official title:
An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Patients With Chronic Kidney Disease

Clinical Trial Summary

This clinical trial is an open, single-center, phase 1 clinical trial to evaluate the safety of allogeneic bone marrow-derived mesenchymal stem cell injection in patients with chronic kidney disease. The purpose is to evaluate the safety for 12 months after administration of Cellgram-CKD 3 times in 10 patients with chronic kidney disease.

Clinical Trial Description

The screening test is performed after the clinical trial subject consents in writing to participate in the clinical trial. Subjects who meet the inclusion/exclusion criteria are registered in the clinical trial, and Cellgram-CKD is injected intravenously by puncturing a vein with a needle. After injecting Cellgram-CKD three times at an interval of 2 weeks (14 days), the subject visits the testing institution at 1 month, 3 months, 6 months, 9 months and 12 months for safety evaluation. However, since the safety of Cellgram-CKD has not been established, proceed as follows. In the first 3 subjects who received the investigational product, if no adverse events of Grade 3 or higher according to the NCI-CTCAE related to the investigational product occur 14 days after the 1st and 2nd administration, and 1 month after the 3rd administration, the remaining subjects were sequentially treated. Register as a member and conduct clinical trials. If an adverse event of Grade 3 or higher according to the NCI-CTCAE standard related to the test drug occurs in two of the first three subjects, the clinical trial is terminated early. is conducted by registering three additional test subjects in the same way as the first. If one or more of the three subjects develops a Grade 3 or higher adverse event related to the investigational product, the clinical trial is terminated early, and the remaining subjects are treated only if all three subjects do not have a Grade 3 or higher adverse reaction related to the investigational product. Register to continue the clinical trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05042206
Study type Interventional
Source Pharmicell Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date November 24, 2021
Completion date September 21, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT05630729 - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management N/A
Completed NCT03293446 - AC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls N/A
Completed NCT04858854 - Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2 N/A
Completed NCT05624840 - Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir
Recruiting NCT05489120 - Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD) N/A
Completed NCT04207203 - Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study N/A
Completed NCT05153174 - Study of Sulphoraphane in Chronic Kidney Disease Phase 1/Phase 2
Recruiting NCT03582982 - Flywheel Exercise for CKD N/A
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Not yet recruiting NCT03348839 - Medico-economic Impacts of NeLLY Service for Not on Dialysis Severe Chronic Kidney Disease N/A
Recruiting NCT04913272 - Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV Phase 2
Recruiting NCT04330807 - Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease N/A
Completed NCT05931978 - Effect of a CKD Dashboard on Patient Activation and Shared Decision Making N/A
Recruiting NCT05543928 - Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism Phase 3
Active, not recruiting NCT06037265 - PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System N/A
Completed NCT04617431 - Application of Wearable Devices to Build a Self-Management Model in Chronic Kidney Disease Patients N/A
Recruiting NCT04336033 - Validation and Evaluation of a Newly Developed Mobile Diet App N/A
Recruiting NCT05138419 - A Pragmatic Approach to CKD Patient Education N/A
Not yet recruiting NCT06394544 - Effects of Brazil Nut Supplementation in Patients With Chronic Kidney Disease Undergoing Conservative Treatment N/A
Recruiting NCT01410617 - The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass Phase 2/Phase 3